Akari Therapeutics Highlights 2025 Progress and Future Plans
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Globenewswire
- Innovative Drug Progress: In 2025, Akari Therapeutics significantly advanced its lead antibody-drug conjugate AKTX-101, demonstrating notable activity against deadly cancers like pancreatic and prostate cancer, which is expected to yield positive outcomes in clinical trials.
- Manufacturing Partnership Initiated: The partnership with global leader WuXi XDC marks the initiation of GMP production for AKTX-101, signifying Akari's transition from a preclinical discovery company to a clinical-focused biotechnology player.
- Intellectual Property Enhancement: Throughout 2025, Akari filed three new patents to protect its unique PH1 payload platform, further solidifying its competitive edge in the oncology sector.
- Future Outlook: 2026 is anticipated to be a pivotal year for Akari, with plans to submit IND applications by the end of the year and initiate Phase 1 clinical trials for AKTX-101, potentially attracting increased investor interest.
AKTX
$0.26+Infinity%1D
Analyst Views on AKTX
Wall Street analysts forecast AKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTX is 4.53 USD with a low forecast of 1.60 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.262
Low
1.60
Averages
4.53
High
7.00
Current: 0.262
Low
1.60
Averages
4.53
High
7.00
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
